Cognitive Pharmaceuticals, Ltd. is an emerging biotech company focused on the discovery and commercialization of treatments for neurological and psychiatric diseases.
Our History:
Cognitive Pharmaceuticals was established in 2001 based on a proprietary platform technology developed at the University of Toledo, College of Pharmacy. In April 2003, Cognitive Pharmaceuticals was registered in Michigan as a for-profit organization [www.medc.michigan.org] [www.michbio.org]. Emphasis is on products with significant return on investment in expanding markets with unmet needs.
A potential treatment of Alzheimer’s disease, a debilitating brain disorder, is presently in development. The mechanism of action of CDD-0102 differs from marketed drugs, targeting both the symptoms – progressive loss of memory and cognitive function – and the underlying cause of the disease – accumulation of amyloid plaque and neurofibrillary tangles. Pharmacodynamic investigation with CDD-0102 demonstrate efficacy in vitro and in an animal model of Alzheimer’s disease. The current focus is the completion of preclinical safety studies with the intention of filing an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA).
The proprietary platform technology – Receptor Based Drug Design (RBDD) – has thus far resulted in nine issued US patents and foreign equivalents. CDD-0304 is presently being investigated for its potential role in alleviating memory and cognitive deficits and behavioral disturbances associated with Alzheimer’s disease and schizophrenia. Additional patent applications are being prosecuted, a number are in preparation. Potentially, this technology will yield additional products, including new approaches in the treatment of pain and addiction.
